HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 62.7 Billion KRW | -51.71% |
| 2022 | 129.84 Billion KRW | 63.23% |
| 2021 | 79.54 Billion KRW | 44.64% |
| 2020 | 54.99 Billion KRW | -37.94% |
| 2019 | 88.62 Billion KRW | 61.17% |
| 2018 | 54.99 Billion KRW | 53.31% |
| 2017 | 35.86 Billion KRW | 167.99% |
| 2016 | 13.38 Billion KRW | -40.79% |
| 2015 | 22.6 Billion KRW | -1.62% |
| 2014 | 22.97 Billion KRW | 71.97% |
| 2013 | 13.36 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 96.7 Billion KRW | 54.22% |
| 2024 Q2 | 104.57 Billion KRW | 8.15% |
| 2023 Q3 | 97.94 Billion KRW | 3.09% |
| 2023 Q2 | 95 Billion KRW | -13.75% |
| 2023 FY | 62.7 Billion KRW | -51.71% |
| 2023 Q1 | 110.16 Billion KRW | -15.16% |
| 2023 Q4 | 62.7 Billion KRW | -35.98% |
| 2022 Q4 | 129.84 Billion KRW | 1.39% |
| 2022 Q3 | 128.06 Billion KRW | 3.18% |
| 2022 Q2 | 124.11 Billion KRW | 29.75% |
| 2022 Q1 | 95.65 Billion KRW | 20.25% |
| 2022 FY | 129.84 Billion KRW | 63.23% |
| 2021 Q4 | 79.54 Billion KRW | 191.35% |
| 2021 Q2 | 46.56 Billion KRW | -1.19% |
| 2021 FY | 79.54 Billion KRW | 44.64% |
| 2021 Q1 | 47.13 Billion KRW | -11.63% |
| 2021 Q3 | 27.3 Billion KRW | -41.37% |
| 2020 Q1 | 68.58 Billion KRW | -21.66% |
| 2020 FY | 54.99 Billion KRW | -37.94% |
| 2020 Q2 | 46.91 Billion KRW | -31.6% |
| 2020 Q3 | 46.97 Billion KRW | 0.12% |
| 2020 Q4 | 53.33 Billion KRW | 13.56% |
| 2019 Q1 | 65.83 Billion KRW | 19.72% |
| 2019 Q2 | 93.17 Billion KRW | 41.54% |
| 2019 FY | 88.62 Billion KRW | 61.17% |
| 2019 Q4 | 87.54 Billion KRW | -12.41% |
| 2019 Q3 | 99.95 Billion KRW | 7.27% |
| 2018 Q1 | 51.2 Billion KRW | 42.76% |
| 2018 Q4 | 54.99 Billion KRW | 33.1% |
| 2018 Q3 | 41.31 Billion KRW | -43.34% |
| 2018 Q2 | 72.91 Billion KRW | 42.39% |
| 2018 FY | 54.99 Billion KRW | 53.31% |
| 2017 Q4 | 35.86 Billion KRW | -2.01% |
| 2017 FY | 35.86 Billion KRW | 167.99% |
| 2017 Q1 | 13.53 Billion KRW | 1.14% |
| 2017 Q2 | 14.28 Billion KRW | 5.5% |
| 2017 Q3 | 36.6 Billion KRW | 156.32% |
| 2016 Q3 | 13.25 Billion KRW | -1.45% |
| 2016 FY | 13.38 Billion KRW | -40.79% |
| 2016 Q4 | 13.38 Billion KRW | 0.99% |
| 2016 Q2 | 13.44 Billion KRW | -0.31% |
| 2016 Q1 | 13.48 Billion KRW | -40.33% |
| 2015 Q1 | 23.31 Billion KRW | 1.45% |
| 2015 Q4 | 22.6 Billion KRW | 33.98% |
| 2015 FY | 22.6 Billion KRW | -1.62% |
| 2015 Q2 | 17.58 Billion KRW | -24.57% |
| 2015 Q3 | 16.87 Billion KRW | -4.05% |
| 2014 Q4 | 22.97 Billion KRW | 27.75% |
| 2014 Q3 | 17.98 Billion KRW | -2.36% |
| 2014 Q2 | 18.42 Billion KRW | 1.23% |
| 2014 Q1 | 18.19 Billion KRW | 36.2% |
| 2014 FY | 22.97 Billion KRW | 71.97% |
| 2013 Q4 | 13.36 Billion KRW | -1.37% |
| 2013 FY | 13.36 Billion KRW | 0.0% |
| 2013 Q1 | 17.04 Billion KRW | 0.0% |
| 2013 Q3 | 13.54 Billion KRW | -15.82% |
| 2013 Q2 | 16.09 Billion KRW | -5.56% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -15463.152% |
| BINEX Co., Ltd. | 53.5 Billion KRW | -17.191% |
| Bioneer Corporation | 44.63 Billion KRW | -40.47% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | -543.766% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | -19.809% |
| CrystalGenomics, Inc. | 32 Billion USD | -95.935% |
| Helixmith Co., Ltd | 20.22 Billion KRW | -209.997% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 86.054% |
| Medy-Tox Inc. | 82.83 Billion KRW | 24.296% |
| Peptron, Inc. | 9.13 Billion KRW | -586.582% |
| Amicogen, Inc. | 149.59 Billion KRW | 58.083% |
| Genexine, Inc. | 67.42 Billion KRW | 7.003% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | -525.656% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | -395.933% |
| ALTEOGEN Inc. | 83.76 Billion KRW | 25.145% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | -82.779% |
| SillaJen, Inc. | 9.69 Billion KRW | -546.673% |
| JETEMA, Co., Ltd. | 130.49 Billion KRW | 51.949% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | -59.323% |
| Genomictree Inc. | 1.83 Billion KRW | -3317.827% |
| MedPacto, Inc. | 8.6 Billion KRW | -628.784% |
| D&D Pharmatech | 8.13 Billion KRW | -670.876% |
| EASY BIO,Inc. | 82.27 Billion KRW | 23.788% |
| GI Innovation, Inc. | 3.72 Billion KRW | -1585.253% |